CD38 and plasma cell myeloma: Visram et al. from the Canadian Myeloma Research Group (CMRG) conducted a large multicentre retrospective cohort study analysing the real-world outcomes of Canadian patients with multiple myeloma relapsing on anti-CD38 monoclonal antibody regimens [5].